Patents by Inventor Christoph Moroni

Christoph Moroni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy for the treatment of cancer and immunosuppression
    Patent number: 9511064
    Abstract: The invention relates to novel Rauwolfia alkaloid derivatives of formula (I) combinations of Rauwolfia alkaloid derivatives and a mitochondrial inhibitor, e.g. metformin, and the use of Rauwolfia alkaloid derivatives in combination with mitochondrial inhibitor for the treatment of cancer and for achieving clinical immunosuppression. The invention also relates to a fluorescence-based method for predicting the sensitivity of a cancer cell towards a compound of formula (I).
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: December 6, 2016
    Assignee: BASILEA PHARMACEUTICA AG
    Inventors: Jens Pohlmann, Don Gary Benjamin, Christoph Moroni
  • COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION
    Publication number: 20150157622
    Abstract: The invention relates to novel Rauwolfia alkaloid derivatives of formula (I) combinations of Rauwolfia alkaloid derivatives and a mitochondrial inhibitor, e.g. metformin, and the use of Rauwolfia alkaloid derivatives in combination with mitochondrial inhibitor for the treatment of cancer and for achieving clinical immunosuppression. The invention also relates to a fluorescence-based method for predicting the sensitivity of a cancer cell towards a compound of formula (I).
    Type: Application
    Filed: July 3, 2013
    Publication date: June 11, 2015
    Inventors: Jens Pohlmann, Don Gary Benjamin, Christoph Moroni
  • COMBINATION OF SYROSINGOPINE AND MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION
    Publication number: 20150157623
    Abstract: The invention relates to a combination of syrosingopine and a mitochondrial inhibitor, e.g. metformin or oligomycin, and the use of the combination of syrosingopine and a mitochondrial inhibitor for the treatment of cancer and for achieving immunosuppression. The invention also relates to a fluorescence-based method for predicting syrosingopine sensitivity of a cancer cell.
    Type: Application
    Filed: February 20, 2015
    Publication date: June 11, 2015
    Inventors: Don BENJAMIN, Marco COLOMBI, Michael HALL, Christoph MORONI
  • Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression
    Patent number: 8993587
    Abstract: The invention relates to a combination of syrosingopine and a mitochondrial inhibitor, e.g. metformin or oligomycin, and the use of the combination of syrosingopine and a mitochondrial inhibitor for the treatment of cancer and for achieving immunosuppression. The invention also relates to a fluorescence-based method for predicting syrosingopine sensitivity of a cancer cell.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: March 31, 2015
    Assignee: Universitat Basel
    Inventors: Don Benjamin, Marco Colombi, Michael Hall, Christoph Moroni
  • COMBINATION OF SYROSINGOPINE AND MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION
    Publication number: 20130281478
    Abstract: The invention relates to a combination of syrosingopine and a mitochondrial inhibitor, e.g. metformin or oligomycin, and the use of the combination of syrosingopine and a mitochondrial inhibitor for the treatment of cancer and for achieving immunosuppression. The invention also relates to a fluorescence-based method for predicting syrosingopine sensitivity of a cancer cell.
    Type: Application
    Filed: January 9, 2012
    Publication date: October 24, 2013
    Inventors: Don Benjamin, Marco Colombi, Michael Hall, Christoph Moroni